AU2007205961B2 - Biomimetic hydroxyapatite synthesis - Google Patents
Biomimetic hydroxyapatite synthesis Download PDFInfo
- Publication number
- AU2007205961B2 AU2007205961B2 AU2007205961A AU2007205961A AU2007205961B2 AU 2007205961 B2 AU2007205961 B2 AU 2007205961B2 AU 2007205961 A AU2007205961 A AU 2007205961A AU 2007205961 A AU2007205961 A AU 2007205961A AU 2007205961 B2 AU2007205961 B2 AU 2007205961B2
- Authority
- AU
- Australia
- Prior art keywords
- particles
- hydroxyapatite
- calcium
- phosphate
- ion source
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 title claims abstract description 62
- 229910052588 hydroxylapatite Inorganic materials 0.000 title claims abstract description 61
- 230000015572 biosynthetic process Effects 0.000 title description 13
- 238000003786 synthesis reaction Methods 0.000 title description 8
- 230000003592 biomimetic effect Effects 0.000 title description 4
- 239000002245 particle Substances 0.000 claims abstract description 104
- 238000000034 method Methods 0.000 claims abstract description 33
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract description 24
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229910001424 calcium ion Inorganic materials 0.000 claims abstract description 11
- 229940085991 phosphate ion Drugs 0.000 claims abstract description 11
- 239000001639 calcium acetate Substances 0.000 claims abstract description 9
- 229960005147 calcium acetate Drugs 0.000 claims abstract description 9
- 235000011092 calcium acetate Nutrition 0.000 claims abstract description 9
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims abstract 2
- 239000000243 solution Substances 0.000 claims description 49
- 229910019142 PO4 Inorganic materials 0.000 claims description 15
- 235000021317 phosphate Nutrition 0.000 claims description 15
- 150000002500 ions Chemical class 0.000 claims description 14
- 239000010452 phosphate Substances 0.000 claims description 13
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 12
- -1 acetate anions Chemical class 0.000 claims description 12
- 239000011575 calcium Substances 0.000 claims description 12
- 229910052791 calcium Inorganic materials 0.000 claims description 12
- 239000000725 suspension Substances 0.000 claims description 9
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 6
- 239000012452 mother liquor Substances 0.000 claims description 5
- 239000011591 potassium Substances 0.000 claims description 5
- 229910052700 potassium Inorganic materials 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 claims description 4
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 3
- 239000013078 crystal Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000004254 Ammonium phosphate Substances 0.000 claims description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
- 235000019289 ammonium phosphates Nutrition 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims description 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 2
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 claims description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 2
- 229910001634 calcium fluoride Inorganic materials 0.000 claims description 2
- 239000000920 calcium hydroxide Substances 0.000 claims description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 2
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 claims description 2
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 claims description 2
- 239000004137 magnesium phosphate Substances 0.000 claims description 2
- 229910000157 magnesium phosphate Inorganic materials 0.000 claims description 2
- 229960002261 magnesium phosphate Drugs 0.000 claims description 2
- 235000010994 magnesium phosphates Nutrition 0.000 claims description 2
- 235000011007 phosphoric acid Nutrition 0.000 claims description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims 1
- 229910052567 struvite Inorganic materials 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000012071 phase Substances 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- 238000002441 X-ray diffraction Methods 0.000 description 10
- XQKKWWCELHKGKB-UHFFFAOYSA-L calcium acetate monohydrate Chemical compound O.[Ca+2].CC([O-])=O.CC([O-])=O XQKKWWCELHKGKB-UHFFFAOYSA-L 0.000 description 10
- 239000000463 material Substances 0.000 description 9
- 239000000872 buffer Substances 0.000 description 7
- 238000003917 TEM image Methods 0.000 description 6
- RMNIZOOYFMNEJJ-UHFFFAOYSA-K tripotassium;phosphate;hydrate Chemical compound O.[K+].[K+].[K+].[O-]P([O-])([O-])=O RMNIZOOYFMNEJJ-UHFFFAOYSA-K 0.000 description 6
- 238000013019 agitation Methods 0.000 description 5
- 239000001506 calcium phosphate Substances 0.000 description 5
- 239000007943 implant Substances 0.000 description 5
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 4
- 239000000919 ceramic Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229920001230 polyarylate Polymers 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 238000007750 plasma spraying Methods 0.000 description 3
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 3
- 229920000515 polycarbonate Polymers 0.000 description 3
- 239000004417 polycarbonate Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229940078499 tricalcium phosphate Drugs 0.000 description 3
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 3
- 235000019731 tricalcium phosphate Nutrition 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- QZTKDVCDBIDYMD-UHFFFAOYSA-N 2,2'-[(2-amino-2-oxoethyl)imino]diacetic acid Chemical compound NC(=O)CN(CC(O)=O)CC(O)=O QZTKDVCDBIDYMD-UHFFFAOYSA-N 0.000 description 2
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 2
- AJTVSSFTXWNIRG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid Chemical compound OCC[NH+](CCO)CCS([O-])(=O)=O AJTVSSFTXWNIRG-UHFFFAOYSA-N 0.000 description 2
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 2
- XCBLFURAFHFFJF-UHFFFAOYSA-N 3-[bis(2-hydroxyethyl)azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound OCCN(CCO)CC(O)CS(O)(=O)=O XCBLFURAFHFFJF-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 2
- 238000009388 chemical precipitation Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 239000001307 helium Substances 0.000 description 2
- 229910052734 helium Inorganic materials 0.000 description 2
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 2
- 238000002173 high-resolution transmission electron microscopy Methods 0.000 description 2
- 238000001027 hydrothermal synthesis Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001444 polymaleic acid Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000001812 pycnometry Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 239000012890 simulated body fluid Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000004627 transmission electron microscopy Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- SVBDYAHXVSJABF-UHFFFAOYSA-N (2-ethenylphenyl)methyl-trimethylazanium Chemical compound C[N+](C)(C)CC1=CC=CC=C1C=C SVBDYAHXVSJABF-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical class ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- WTOROJZGWRPWSM-UHFFFAOYSA-N 1-amino-4-hydroxy-3,3-bis(hydroxymethyl)butane-2-sulfonic acid Chemical compound NCC(S(O)(=O)=O)C(CO)(CO)CO WTOROJZGWRPWSM-UHFFFAOYSA-N 0.000 description 1
- XKZQKPRCPNGNFR-UHFFFAOYSA-N 2-(3-hydroxyphenyl)phenol Chemical class OC1=CC=CC(C=2C(=CC=CC=2)O)=C1 XKZQKPRCPNGNFR-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- NUFBIAUZAMHTSP-UHFFFAOYSA-N 3-(n-morpholino)-2-hydroxypropanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CN1CCOCC1 NUFBIAUZAMHTSP-UHFFFAOYSA-N 0.000 description 1
- RZQXOGQSPBYUKH-UHFFFAOYSA-N 3-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound OCC(CO)(CO)NCC(O)CS(O)(=O)=O RZQXOGQSPBYUKH-UHFFFAOYSA-N 0.000 description 1
- VTOWJTPBPWTSMK-UHFFFAOYSA-N 4-morpholin-4-ylbutane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCN1CCOCC1 VTOWJTPBPWTSMK-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 241001286462 Caio Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 1
- 238000001016 Ostwald ripening Methods 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- SFPNSCZLRJDTGT-SDNWHVSQSA-N Polyoxyethylene (600) monoricinoleate Polymers CCCCCCC(O)C\C=C\CCCCCCCC(=O)OCCC SFPNSCZLRJDTGT-SDNWHVSQSA-N 0.000 description 1
- NKSOSPOXQKNIKJ-CLFAGFIQSA-N Polyoxyethylene dioleate Polymers CCCCCCCC\C=C/CCCCCCCC(=O)OCCOC(=O)CCCCCCC\C=C/CCCCCCCC NKSOSPOXQKNIKJ-CLFAGFIQSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229920002642 Polysorbate 65 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical class C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 239000003462 bioceramic Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000002639 bone cement Substances 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000000551 dentifrice Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical class CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- 239000002019 doping agent Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000010128 melt processing Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 229920000141 poly(maleic anhydride) Polymers 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920006149 polyester-amide block copolymer Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000223 polyglycerol Chemical class 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940099511 polysorbate 65 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000011164 primary particle Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011163 secondary particle Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001778 solid-state sintering Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009974 thixotropic effect Effects 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 229940062627 tribasic potassium phosphate Drugs 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/12—Phosphorus-containing materials, e.g. apatite
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
A method for preparing nanoscale hydroxyapatite particles by combining an amount of a calcium ion source, which includes calcium acetate, and an amount of a phosphate ion source, wherein the amounts are sufficient to produce nanoscale hydroxyapatite particles and the amounts are combined under ambient conditions to produce the hydroxyapatite particles. Nanoscale hydroxyapatite particles are also presented.
Description
WO 2007/084858 PCT/US2007/060505 5 BIOMIMETIC HYDROXYAPATITE SYNTHESIS CROSS REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application Serial No. 60/758,207, which was filed on January 12, 2006, the disclosure of which is incorporated 10 herein by reference. STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH The U.S. Government has a paid-up license in this invention and the right in limited circumstances to require the patent owner to license others on reasonable terms as provided for by the terms of grant DGE033196 awarded by the National Science 15 Foundation. BACKGROUND OF THE INVENTION Hydroxyapatite (HAp, chemical formula Caio(PO 4
)
6
(OH)
2 ) has attracted the attention of researchers over the past thirty years as an implant material because of its excellent biocompatibility and bioactivity. HAp has been extensively used in medicine 20 for implant fabrication. It is commonly the material of choice for the fabrication of dense and porous bioceramics. Its general uses include biocompatible phase-reinforcement in composites, coatings on metal implants and granular fill for direct incorporation into human tissue. It has also been extensively investigated for non-medical applications such as a packing material/support for column chromatography, gas sensors and catalysts, as a 25 host material for lasers, and as a plant growth substrate. Previously explored methods of hydroxyapatite synthesis for particles include plasma spraying, hydrothermal synthesis, freeze drying, sol-gel, phase transformation, mechanochemical synthesis, chemical precipitation, and precipitation in simulated body 1 2 Fluid (SBF). All of these methods produce products with varying levels of purity, size, crystallinity, and yield. Plasma spraying, hydrothermal synthesis, sol-gel, phase transformation, mechanochemical synthesis, and chemical precipitation require elevated temperatures and/or extreme pH values in the fabrication of 5 hydroxyapatite. These conditions can raise important questions among biologists when considering the material for in vivo applications because they are not biomimetic and, in most cases, do not yield biomimetic structures or morphologies. Furthermore, precipitation in simulated body fluid has such a low yield or long reaction time, it is not practical for use in manufacturing implants. 10 Therefore, a need exists for hydroxyapatite synthesis to take place at room temperature and optional neutral pH to allow the exploration of synthesis with live cells, including those in living organisms. 15 SUMMARY OF THE INVENTION In one aspect, the invention provides a method for preparing nanoscale hydroxyapatite particles comprising: (a) combining an amount of a calcium ion source comprising calcium acetate and an amount of a phosphate ion source, wherein said amounts are 20 sufficient to produce nanoscale hydroxyapatite particles and said amounts are combined under essentially ambient conditions to produce said hydroxyapatite particles; and (b) stopping the calcium ion source from reacting with the phosphate ion source at a point in time that is from 1 minute to 60 minutes after they are 25 initially combined to produce hydroxyapatite particles comprising a BET surface area between about 200 and about 3000 m 2 /g and a particle size wherein the largest dimension of any particle is between about 1 nm and about 9 nm, said particles comprising crystals with a dominant lattice spacing of about 0.28 nm. 30 In one embodiment, a stable colloidal suspension of the hydroxyapatite particles suspended in a biocompatible ionic solution is provided.
WO 2007/084858 PCT/US2007/060505 Also provided is a kit for use in preparing nanoscale nyaroxyapame put ants, wherein the kit includes (a) an amount of a calcium ion source, which includes calcium acetate, and (b) an amount of a phosphate ion source, wherein the amounts are sufficient to produce nanoscale hydroxyapatite particles when combined under ambient conditions. 5 BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1 a-d are transmission electron microscopy (TEM) images of particles prepared according to the method of Example 2; FIGS. 2a-b are TEM images of particles prepared according to the method of Example 3; 10 FIG. 2c is a TEM image of particles prepared according to the method of Example 3 at a higher magnification than the images of FIGS. 2a-b; FIG. 2d is a TEM image of particles prepared according to the method of Example 3 showing a particle size distribution of +/- 10nm; FIG. 2e is a high resolution transmission electron microscopy (HRTEM) image of 15 particles prepared according to the method of Example 3; FIG. 3a is an XRD spectrum corresponding to HAp particles prepared according to a method of Example 1; FIG. 3b is an XRD spectrum corresponding to HAp particles prepared according to the method of Example 2; 20 FIG. 3c is an XRD spectrum corresponding to HAp particles prepared according to a method of Example 1, wherein the reactant concentrations were halved; and FIG. 3d is an XRD spectrum corresponding to HAp particles prepared according to a method of Example 1, wherein the particles were heat treated at 900*C for 2 hours. 25 3 WO 2007/084858 PCT/US2007/060505 DETAILED DESCRIPTION OF THE INVENTION The present invention is related to methods for preparing nanoscale HAp particles and the HAp particles prepared therewith. Kits for use in preparing the particles and colloids containing the particles are also presented. 5 Hydroxyapatite has reported uses for biomedical, chromatographic, and piezoelectric applications and has been synthesized by various techniques. However, reaction conditions for the preparation of HAp such as high temperatures, high pressures and extreme pH values, as well as low yield, vigorous washing requirements, and long reaction times limit biological applications. 10 The methods of the present invention permit the formation under mild reaction conditions of HAp under conditions suitable for the above uses, especially biological use. The method involves combining an amount of a calcium ion source, which includes calcium acetate, and an amount of a phosphate ion source, wherein the amounts are sufficient to produce nanoscale HAp particles and the amounts are combined under 15 essentially ambient conditions to produce the HAp particles. Suitable phosphate ion sources include, but are not limited to, one or more of potassium or sodium orthophosphate; orthophosphoric acid; Group I phosphates, preferably monobasic, dibasic, or tribasic potassium or sodium phosphate; magnesium phosphate; ammonium phosphate; and the like. Potassium or sodium orthophosphate is 20 preferred. In addition to calcium acetate, the calcium ion source may include one or more of calcium hydroxide, calcium oxalate, calcium acetate, calcium nitrate, calcium phosphate, calcium carbonate, calcium fluoride, and calcium chloride. Calcium acetate alone is preferred. The calcium ion source, the phosphate ion source, or both are in solution prior to 25 combining the sources. Preferably, the solution contains one or more of water, buffer, solvent, simulated body fluid, or fortified cell medium with or without serum. Suitable buffers include, but are not limited to, N-(2-hydroxyethyl)-piperazine-N'- 2 ethanesulfonic acid (HEPES), 2-(bis(2-hydroxyethyl)amino)-2-(hydroxymethyl)propane 1,3-diol (BIS-TRIS), 3-(N-Morpholino)-propanesulfonic acid (MOPS), N-(2 4 WO 2007/084858 PCT/US2007/060505 Acetamido)-2-aminoethanesulfonic acid (ACES), N-(2-Acetamido)iminodiacetic Acid (ADA), N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic Acid (BES), 3-[N,N-bis(2 hydroxyethyl)amino]-2-hydroxypropanesulfonic acid (DIPSO), 4-(N morpholino)butanesulfonic acid (MOBS), 3-[N-morpholino]-2-hydroxypropanesulfonic 5 acid (MOPSO), piperazine-1,4-bis(2-ethanesulfonic acid) (PIPES), 3-[N Tris(hydroxymethyl)methylamino]-2-hydroxypropanesulfonic acid (TAPSO), N Tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid (TES), and acetic acid. A preferred buffer is acetic acid. If a particular ion source is not in solution, the source is in a solid phase. 10 An optional step includes agitating the combination until HAp is formed. Agitating the combination accelerates the formation of hydroxyapatite. As used herein, the term "agitate" refers to mechanical movement, for example, vibrating, vortexing, swirling, shaking, ultrasonicating, stirring, or the like that causes mixing. Mechanical movements include movements performed by hand. 15 When the precursor composition is completely mixed, an extremely viscous gel is formed. This thixotropic material exhibits shear thinning after further intense agitation and returns to a milky solution. Optionally, this solution is allowed to age for a period between 2 minutes and 10 days. During the aging process, additional agitation may or may not be applied to continue mixing. The aging time allows Ostwald ripening of the 20 particles, therefore, the particles aged longer exhibit a larger particle size. Essentially ambient conditions are employed. A preferred temperature range is between -10"C and 45"C. At room temperature, HAp particles are typically produced within 1 minute to an hour. Combining the sources while heating will speed up the rate of reaction to more quickly produce HAp, while combining the ion sources while cooling 25 will decrease the rate at which HAp particles form. During the course of the reaction, a pH swing may occur, which is varied with the calcium to phosphate stoichiometry. A preferred embodiment, in which the calcium to phosphate ratio is about 1.67, exhibits a pH swing of 12 down to 7 over the time of a 4 hour reaction. The pH of the gel phase is 12; just after the shear thinning and return to 30 solution, the pH is 10; after 3 hours of reaction, the pH is 8; and after 4 hours of reaction, 5 WO 2007/084858 PCT/US2007/060505 the pH returns to neutral. The time to neutral, however, also depends on the employment or omission of agitation throughout the reaction that may enhance kinetics and diffusion of the ions in the formation of hydroxyapatite. The employment of a buffer as the reaction medium moderates the pH change, 5 which affects the product formed. Hydroxyapatite is formed, but secondary phases of calcium phosphate and calcium carbonate may be additionally formed, but can be remedied through process variations, for example, bubbling with nitrogen, addition of chelating agents, or use of additional pH adjustments or buffers. Another optional step includes adding one or more dopant ions suitable for 10 substitution into the HAp lattice. Such ions are readily determinable by one of skill in the art. Suitable ions include, but are not limited to, magnesium, fluorine, chlorine, potassium, iron, carbonate, sodium, and the like. The HAp particles of the present invention can also be doped with ions of one or more rare earth elements. Following the aging process, a washing step can be performed. This step 15 includes, for example, filtration, centrifuging, and/or liquid replacement. Centrifuging or liquid replacement are preferred. Minimal washing cycles are needed because of the non toxic nature of the ions left in solution. In one embodiment, the citrate wash disclosed in U.S. Patent No. 6,921,544, the contents of which are incorporated herein by reference in their entirety, is used to remove at least a portion of an amorphous phase if the 20 amorphous phase is considered an undesired impurity. To produce solid hydroxyapatite, the solution is dried. Suitable drying techniques are readily determinable by those of skill in the art. Preferred drying techniques include evaporative and sublimation-based drying methods, for example, oven drying and freeze drying. 25 The methods according to the present invention can take place in any suitable reaction system. An exemplary system includes a flow reactor for continuous production of hydroxyapatite. Powdered HAp particles produced according to the methods of the present invention are also presented. The HAp particles have a BET surface area between about 6 WO 2007/084858 PCT/US2007/060505 200 and about 3000 m 2 /g and a particle size between about 1 nm and about 9 nm. In one embodiment, the particles have a dispersed particle size between about 1 and about 9 nm. The term "dispersed" is defined herein in the context of colloidal chemistry where the particles maintain an inter-particle spacing such that no physical contact is made between 5 the particles. The term "aggregated" is defined herein as adjacent particles having no inter-particle spacing and making contact with the nearest neighboring particles. In another embodiment, the particles are aggregated and have an aggregated particle size equal to or greater than about 2 nm, preferably between about 2nm and about 5 mm. The composition of the powdered HAp particles is stoichiometric or non 10 stoichiometric with respect to calcium and phosphate. For example, the XRD diffraction pattern of FIG. 3d represents the results of a standard test for stoichiometry. FIG. 3d shows the presence of peaks corresponding to tricalcium phosphate (TCP) after the sample was heat treated at 900C for 2 hours. The presence of TCP indicates a non stoichiometric composition and/or an amorphous phase. In one embodiment, at least a 15 portion of the composition includes an amorphous phase. In one embodiment, the ratio of calcium to phosphate in the HAp particles is between 1.25 and 2.5. The HAp particles exhibit a spherical or non-spherical morphology. The term "spherical" is used herein to mean equiaxed particles having either a primary or secondary particle structure. 20 Given that hydroxyapatite has no toxicity and its components are low cost, such a technology presents great promise for a range of applications. HAp particles having the size distribution of the present invention are effective in drug delivery because they are more capable of penetrating the cellular wall and carry a much higher surface area for adsorption of drug molecules. The range also allows the 25 particles to be used intravenously as a drug therapy or for transdermal drug delivery. The size range is also important in biomaterial applications because it is close to what is seen naturally in the body. Being smaller, it will also be more readily processable by cells and tissues for regeneration and resorption. Devices based on hydroxyapatite are typically in the form of polycrystalline 30 ceramics, polymer-ceramic composites, or films on a metallic surface such as titanium. 7 WO 2007/084858 PCT/US2007/060505 The powders produced in this invention can be used in conventional processes to make all three forms of materials, using conventional methods such as solid state sintering for polycrystalline ceramics, polymer-melt processing for polymer-ceramic composites and plasma spraying for hydroxyapatite-coated titanium metal. The particles of this invention 5 can be grown directly onto the metal surfaces without the need for any high temperature processing. The hydroxyapatite of the present invention is also useful in the preparation of compounds for use as granular fill for direct incorporation into the hard tissues of humans or other animals, and as bone implantable materials. The present invention thus includes 10 granular fill compounds, bone implant materials, tooth filling compounds, bone cements and dentifrices containing the hydroxyapatite of the present invention. The products are formulated and prepared by substituting the hydroxyapatite of the present invention for hydroxyapatite in conventional hydroxyapatite-based products. The compounds may be prepared from metallic and polymeric hydroxyapatite composites. 15 Suitable polymers include polysaccharides, poly(alkylene oxides), polyarylates, for example those disclosed in U.S. Patent No. 5,216,115, block co-polymers of poly(alkylene oxides) with polycarbonates and polyarylates, for example those disclosed in U.S. Patent No. 5,658,995, polycarbonates and polyarylates, for example those disclosed in U.S. Patent No. 5,670,602, free acid polycarbonates and polyarylates, for 20 example those disclosed in U.S. Patent No. 6,120,491, polyamide carbonates and polyester amides of hydroxy acids, for example those disclosed in U.S. Patent No. 6,284,862, polymers of L-tyrosine derived diphenol compounds, including polythiocarbonates and polyethers, for example those disclosed in U.S. Patent No. RE37,795, strictly alternating poly(alkylene oxide) ethers, for example those disclosed in 25 U.S. Patent No. 6,602,497, polymers listed on the United States FDA "EAFUS" list, including polyacrylamide, polyacrylamide resin, modified poly(acrylic acid-co hypophosphite), sodium salt polyacrylic acid, sodium salt poly(alkyl(C 16-22) acrylate), polydextrose, poly(divinylbenzene-co-ethylstyrene), poly(divinylbenzene-co trimethyl(vinylbenzyl)ammonium chloride), polyethylene (m.w. 2,00-21,000), 30 polyethylene glycol, polyethylene glycol (400) dioleate, polyethylene (oxidized), polyethyleneimine reaction product with 1,2-dichloroethane, polyglycerol esters of fatty 8 WO 2007/084858 PCT/US2007/060505 acids, polyglyceryl phthalate ester of coconut oil fatty acids, polyisobutylene (min. m.w. 37,000), polylimonene, polymaleic acid, polymaleic acid, sodium salt, poly(maleic anhydride), sodium salt, polyoxyethylene dioleate, polyoxyethylene (600) dioleate, polyoxyethylene (600) mono-rici noleate, polyoxyethylene 40 monostearate, 5 polypropylene glycol (m.w. 1,200-3,000), polysorbate 20, polysorbate 60, polysorbate 65, polysorbate 80, polystyrene, cross-linked, chloromethylated, then aminated with trimethylamine, dimethylamine, diethylenetriamine, or triethanolamine, polyvinyl acetate, polyvinyl alcohol, polyvinyl polypyrrolidone, and polyvinylpyrrolidone, and polymers listed in U.S. Patent No. 7,112,417, the disclosures of all of which are 10 incorporated herein by reference in their entirety. Also presented is a kit for use in preparing nanoscale HAp particles of the present invention. The kit includes (a) an amount of a calcium ion source comprising calcium acetate and (b) an amount of a phosphate ion source, wherein the amounts are sufficient to produce nanoscale HAp particles when combined under ambient conditions. The kit 15 can be used to prepare HAp particles prior to the introduction of the particles into a patient. Alternatively, the kit can be used to combine components (a) and (b) in a patient in need thereof for the preparation, and subsequent deposit, of HAp particles in vivo. The two ion sources are provided in separate containers. Other components may be present depending upon the intended therapeutic use. 20 Yet another aspect of the present invention includes a stable colloidal suspension with nanoscale HAp particles suspended in a biocompatible ionic solution prepared according to the methods of the present invention, wherein the ionic solution includes physiological concentrations of phosphate and acetate anions and sodium or potassium cations. Also presented is a stable colloidal suspension with the HAp particles of the 25 present invention suspended in a biocompatible ionic solution. A suitable ionic solution is readily determinable by one of skill in the art. In one embodiment, the ionic solution includes the mother liquor from which the hydroxyapatite particles were produced. The mother liquor can be formulated to produce an ionic buffer upon HAp formation. For example, the mother liquor could form a phosphate buffered 30 saline (PBS) solution upon formation of HAp. In another embodiment, the ionic solution 9 WO 2007/084858 PCT/US2007/060505 includes a solution prepared independently of the hydroxyapatite particles, for example, one of the aforementioned buffers. The following non-limiting examples set forth herein below illustrate certain aspects of the invention. 5 EXAMPLES Example 1 - Room temperature crystallization of hydroxyapatite in water. Calcium acetate hydrate (99% Acros Organics, Belgium, CAS # 114460-21-8) and potassium orthophosphate hydrate (Acros Organics, Belgium, CAS# 27176-10-9) were used as reactants for the synthesis of hydroxyapatite. First, a 1.0 molal calcium 10 acetate hydrate solution was made using distilled, deionized water. Then, a 0.6 molal solution of potassium orthophosphate hydrate was made using distilled, deionized water. Equal volumes of each were then measured out for the reaction to create a calcium to phosphate ratio of 1.67 (final concentrations of ions if they were to remain in solution would be 0.5m/0.3m). A 100 mL reaction required 50mL of the calcium solution to be 15 measured and poured into a beaker and 50mL of the phosphate solution to be added. Agitation via vortexing was then performed until and through the gelation stage. Once the gel returned to solution, the slurry was then allowed to age for 2 minutes. The concentrate was then dried in an oven at 70"C for 24 hours and desiccated until use or immediately atomized onto a Transmission Electron Microscopy (TEM) grid for 20 characterization. X-Ray diffraction (XRD) confirmed the phase formed was hydroxyapatite with no detectable secondary phases or peaks present. FIG. 3a is an XRD diffraction pattern corresponding the HAp particles prepared according to this method, which were washed followed by drying in a 70'C oven. The broadness of the peaks in FIG. 3a indicates 25 nanoscale particles. Furthermore, the peaks match the standard reference peaks for hydroxyapatite. Helium pycnometry confirms an average particulate density of 2.4 g/cm 3 . 10 WO 2007/084858 PCT/US2007/060505 FIG. 3c is an XRD diffraction pattern corresponding to HAp particles prepared according to this method, wherein the reactant concentrations were halved. FIG. 3c also confirms the presence of HAp particles. Example 2 - Room temperature crystallization of hydroxyapatite in water. 5 Hydroxyapatite was prepared according to the method of Example 1. However, a 2.0 molal calcium acetate hydrate solution and a 1.2 molal solution of potassium orthophosphate hydrate were used. The final concentrations of ions if they were to remain in solution after mixing would be 1.0m/0.6m. TEM images of the resulting hydroxyapatite particles are shown in FIGS. la-d. 10 These images show lattice fringes indicating crystallinity of the particles and also show relatively uniform particle size and morphology. The XRD diffraction pattern is shown in FIG. 3b, which also confirms the presence of HAp particles. Example 3 - Room temperature crystallization of hydroxyapatite in a self 15 buffering solution. Calcium acetate hydrate and potassium orthophosphate hydrate solutions were prepared as described in Example 1. The potassium orthophosphate hydrate solution was divided in half and acetic acid was added to one of the two portions until the pH of the solution was 7.4 (volume depends on total solution volume, for example 500mL solution 20 needs about 23mL of glacial acetic acid). Proportional amounts of each of the three solutions were then measured out to create a calcium to phosphate ratio of 1.67 and pH of 7.4 (final concentrations of ions if they were to remain in solution would be 0.5m/0.3m). A 20 mL reaction required 1OmL of the calcium solution to be measured and poured into a beaker and 8.5mL of the phosphate solution (unadjusted) to be added to the calcium 25 solution followed by 1.5mL of the pH adjusted solution. Agitation via stirring with a glass rod was then performed until the solution appeared completely mixed and white (a gelation is not seen). The slurry was not aged. The concentrate or solution was then dried in an oven at 70 0 C for 24 hours and desiccated until use or immediately atomized onto a TEM grid for characterization. 11 12 X-Ray diffraction confirmed the phase formed was hydroxyapatite with no detectable secondary phases or peaks present. An average density of 2.2 g/cm 3 was determined via Helium pycnometry. TEM images of the resulting hydroxyapatite particles are shown in FIGS. 2a-e. 5 These images show lattice fringes indicating crystallinity of the particles and also show relatively uniform particle size and morphology. Dispersed particles having a particle size less than I Onm are shown. The foregoing examples and description of the preferred embodiments should be taken as illustrating, rather than as limiting the present invention as defined by the claims. 10 As will be readily appreciated, numerous variations and combinations of the features set forth above can be utilized without departing from the present invention as set forth in the claims. Such variations are not regarded as a departure from the spirit and script of the invention, and all such variations are intended to be included within the scope of the following claims. 15 Comprises/comprising and grammatical variations thereof when used in this specification are to be taken to specify the presence of stated features, integers, steps or components or groups thereof, but do not preclude the presence or addition of one or more other features, integers, steps, components or groups thereof. 20
Claims (19)
1. A method for preparing nanoscale hydroxyapatite particles comprising: (a) combining an amount of a calcium ion source comprising calcium acetate and an amount of a phosphate ion source, wherein said amounts are 5 sufficient to produce nanoscale hydroxyapatite particles and said amounts are combined under essentially ambient conditions to produce said hydroxyapatite particles; and (b) stopping the calcium ion source from reacting with the phosphate ion source at a point in time that is from 1 minute to 60 minutes after they are 10 initially combined to produce hydroxyapatite particles comprising a BET surface area between about 200 and about 3000 m 2 /g and a particle size wherein the largest dimension of any particle is between about 1 nm and about 9 nm, said particles comprising crystals with a dominant lattice spacing of about 0.28 nm.
2. The method of claim 1, wherein said phosphate ion source is selected from 15 the group consisting of potassium orthophosphate, sodium orthophosphate, orthophosphoric acid, Group 1 phosphates, magnesium phosphate, ammonium phosphate, and a combination of two or more thereof.
3. The method of claim 1 or 2, wherein said calcium ion source further comprises calcium hydroxide, calcium oxalate, calcium nitrate, calcium 20 phosphate, calcium carbonate, calcium fluoride, calcium chloride, or a combination of two or more thereof.
4. The method of any one of claims 1 to 3, further comprising adding a buffer solution to the combination.
5. Powdered hydroxyapatite particles comprising a BET surface area 25 between about 200 and about 3000 m 2 /g and a particle size wherein the largest dimension of any particle is between about 1 nm and about 9 nm, said particles comprising crystals with a dominant lattice spacing of about 0.28 nm. 14
6. The powdered hydroxyapatite of claim 5 consisting essentially of particles having a dispersed particle size wherein the largest dimension of any particle is between about 1 nm and about 9 nm.
7. The powdered hydroxyapatite of claim 5 consisting essentially of particles 5 having an aggregated particle size wherein the largest dimension of any particle is between about 2 nm and about 5mm.
8. The powdered hydroxyapatite of any one of claims 5 to 7, further comprising an amorphous phase.
9. The powdered hydroxyapatite of any one of claims 5 to 8, wherein the ion 10 ratio of calcium to phosphate is between 1.25 and 2.5.
10. The powdered hydroxyapatite of any one of claims 5 to 9, wherein said particles are doped with one or more ions suitable for substitution into the HAp lattice.
11. A stable colloidal suspension comprising nanoscale hydroxyapatite 15 particles prepared by the method of any one of claims 1 to 4 suspended in a biocompatible ionic solution, wherein said ionic solution comprises physiological concentrations of phosphate and acetate anions and sodium or potassium cations.
12. The suspension of claim 11, wherein said ionic solution is formed from the 20 mother liquor from which said hydroxyapatite particles were produced.
13. The suspension of claim 11 or 12, wherein said ionic solution comprises a solution prepared independently of the hydroxyapatite particles.
14. A stable colloidal suspension comprising the hydroxyapatite particles of any one of claims 5 to 10, suspended in a biocompatible ionic solution. 15
15. The suspension of claim 14, wherein said ionic solution is formed from the mother liquor from which said hydroxyapatite particles were produced.
16. The suspension of claims 14 or 15, wherein said ionic solution comprises a solution prepared independently of the hydroxyapatite particles. 5
17. A method of preparing nanoscale hydroxyapatite particles substantially as hereinbefore described with reference to the examples.
18. Powdered hydroxyapatite particles substantially as hereinbefore described with reference to the examples.
19. The powdered hydroxyapatite of any one of claims 5 to 10 further 10 comprising a drug. WATERMARK PATENT & TRADE MARK ATTORNEYS
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75820706P | 2006-01-12 | 2006-01-12 | |
US60/758,207 | 2006-01-12 | ||
PCT/US2007/060505 WO2007084858A2 (en) | 2006-01-12 | 2007-01-12 | Biomimetic hydroxyapatite synthesis |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2007205961A1 AU2007205961A1 (en) | 2007-07-26 |
AU2007205961B2 true AU2007205961B2 (en) | 2013-03-14 |
Family
ID=38288352
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2007205961A Ceased AU2007205961B2 (en) | 2006-01-12 | 2007-01-12 | Biomimetic hydroxyapatite synthesis |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1981514A2 (en) |
AU (1) | AU2007205961B2 (en) |
WO (1) | WO2007084858A2 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8287914B2 (en) | 2006-01-12 | 2012-10-16 | Rutgers, The State University Of New Jersey | Biomimetic hydroxyapatite synthesis |
PL210026B1 (en) * | 2009-03-17 | 2011-11-30 | Akademia Górniczo Hutnicza Im Stanisława Staszica | Method of manufacturing the high-porous, bioactive calcium phosphate implant material |
WO2011124234A1 (en) * | 2010-04-07 | 2011-10-13 | Eman Ismail Abd El-Gawad | Repair of fragmented dna and treatment of heavy metal intoxication by intravenous injection of nano-hydroxyapatite |
KR20180089389A (en) | 2015-09-25 | 2018-08-08 | 클린 월드 테크놀로지스 엘티디. | Preparation of calcium phosphate composition |
CN106824236A (en) * | 2017-02-21 | 2017-06-13 | 西华师范大学 | Caesium or the hydroxyapatite catalyst of calcic of potassium doping and its preparation method and application |
CN110775953B (en) * | 2019-11-27 | 2023-03-31 | 中山市科信生物技术有限公司 | Method for synthesizing thermodynamically stable hydroxyapatite with microscopic kinetic reaction limitation |
CN112875665B (en) * | 2021-02-07 | 2022-11-01 | 吉林大学 | Hydroxyapatite microspheres for injection filling preparation and preparation method thereof |
CN113797395B (en) * | 2021-09-17 | 2023-02-21 | 北京爱康宜诚医疗器材有限公司 | Nano hydroxyapatite/block copolymer composite material and preparation method thereof |
CN115557480A (en) * | 2022-10-28 | 2023-01-03 | 南京市儿童医院 | Synthesis method of cobalt-doped hydroxyapatite microspheres |
CN116832223B (en) * | 2023-07-27 | 2024-01-30 | 重庆生物智能制造研究院 | Medical absorbable calcium phosphate salt/polyester composite material and preparation method thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6013591A (en) * | 1997-01-16 | 2000-01-11 | Massachusetts Institute Of Technology | Nanocrystalline apatites and composites, prostheses incorporating them, and method for their production |
WO2005123579A1 (en) * | 2004-06-15 | 2005-12-29 | Promimic Ab | Synthetic nano-sized crystalline calcium phosphate and method of production |
WO2007009477A1 (en) * | 2005-07-21 | 2007-01-25 | Lisopharm Ag | Method for producing hydroxyapatite particles, in particular subnanodisperse hydroxyapatite particles in a matrix |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6387414B1 (en) * | 1999-08-05 | 2002-05-14 | Nof Corporation | Method for preparing hydroxyapatite composite and biocompatible material |
US6921544B2 (en) * | 2001-03-06 | 2005-07-26 | Rutgers, The State University | Magnesium-substituted hydroxyapatites |
-
2007
- 2007-01-12 WO PCT/US2007/060505 patent/WO2007084858A2/en active Application Filing
- 2007-01-12 EP EP07718197A patent/EP1981514A2/en not_active Withdrawn
- 2007-01-12 AU AU2007205961A patent/AU2007205961B2/en not_active Ceased
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6013591A (en) * | 1997-01-16 | 2000-01-11 | Massachusetts Institute Of Technology | Nanocrystalline apatites and composites, prostheses incorporating them, and method for their production |
WO2005123579A1 (en) * | 2004-06-15 | 2005-12-29 | Promimic Ab | Synthetic nano-sized crystalline calcium phosphate and method of production |
WO2007009477A1 (en) * | 2005-07-21 | 2007-01-25 | Lisopharm Ag | Method for producing hydroxyapatite particles, in particular subnanodisperse hydroxyapatite particles in a matrix |
Also Published As
Publication number | Publication date |
---|---|
EP1981514A2 (en) | 2008-10-22 |
WO2007084858A2 (en) | 2007-07-26 |
AU2007205961A1 (en) | 2007-07-26 |
WO2007084858A3 (en) | 2007-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8673252B2 (en) | Biomimetic hydroxyapatite synthesis | |
AU2007205961B2 (en) | Biomimetic hydroxyapatite synthesis | |
Shepherd et al. | Substituted hydroxyapatites for bone repair | |
US8337904B2 (en) | Magnesium-substituted hydroxyapatites | |
Uskoković et al. | Phase composition control of calcium phosphate nanoparticles for tunable drug delivery kinetics and treatment of osteomyelitis. I. Preparation and drug release | |
Ullah et al. | Impact of structural features of Sr/Fe co-doped HAp on the osteoblast proliferation and osteogenic differentiation for its application as a bone substitute | |
EP2046405B1 (en) | Biomaterials, their preparation and use | |
CN102815935B (en) | Ceramic particle group and use thereof | |
Sousa et al. | Mesoporous silica/apatite nanocomposite: special synthesis route to control local drug delivery | |
Prokopowicz et al. | Biphasic composite of calcium phosphate-based mesoporous silica as a novel bone drug delivery system | |
Taherkhani et al. | Influence of strontium on the structure and biological properties of sol–gel-derived mesoporous bioactive glass (MBG) powder | |
Choi et al. | Sustained plasmid DNA release from dissolving mineral coatings | |
US20080206554A1 (en) | Hydroxyapatite With Controllable Size And Morphology | |
US20070065355A1 (en) | Rod-shaped apatite crystals having a specific length-to-width ratio | |
Miller et al. | Testing of Brushite (CaHPO 4· 2 H 2 O) in Synthetic Biomineralization Solutions and In Situ Crystallization of Brushite Micro‐Granules | |
EP2185133B1 (en) | Calcium phosphate microspheres drug delivery system and process for preparing the same | |
Jariya et al. | Drug delivery and antimicrobial studies of chitosan-alginate based hydroxyapatite bioscaffolds formed by the Casein micelle assisted synthesis | |
Tas | Submicron spheres of amorphous calcium phosphate forming in a stirred SBF solution at 55 C | |
Díaz-Cuenca et al. | Biocompatible calcium phosphate-based ceramics and composites | |
El-Fiqi et al. | Highly bioactive bone cement microspheres based on α-tricalcium phosphate microparticles/mesoporous bioactive glass nanoparticles: Formulation, physico-chemical characterization and in vivo bone regeneration | |
ES2906408T3 (en) | Stabilized amorphous calcium phosphate doped with fluoride ions and a process for producing the same | |
Hayakawa | In vitro degradation behavior of hydroxyapatite | |
Ullah et al. | Physicochemical Properties and Simulation of Magnesium/Zinc Binary-Substituted Hydroxyapatite with Enhanced Biocompatibility and Antibacterial Ability | |
JP2019210186A (en) | Phosphate sustained-release by silicon-based hollow particle including phosphate compound | |
Bigi et al. | Department of Chemistry “Giacomo Ciamician”, University of Bologna, Bologna, Italy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |